These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32470093)

  • 1. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
    Ding Y; Ding K; Yang H; He X; Mo W; Ding X
    PLoS One; 2020; 15(5):e0234058. PubMed ID: 32470093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
    Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
    BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
    Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
    Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies.
    Petrelli F; Coinu A; Lonati V; Cabiddu M; Ghilardi M; Borgonovo K; Barni S
    Anticancer Drugs; 2016 Aug; 27(7):702-8. PubMed ID: 27058707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
    Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
    Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
    Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
    Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
    Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
    Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
    Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
    Dai XL; Han ZB; Yang YT; Qiu J; Liu YF; Feng YZ
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):517-22. PubMed ID: 25907177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
    Zhu W; Xu B
    PLoS One; 2015; 10(8):e0136268. PubMed ID: 26291454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.
    Tacca O; Penault-Llorca F; Abrial C; Mouret-Reynier MA; Raoelfils I; Durando X; Achard JL; Gimbergues P; Curé H; Chollet P
    Oncologist; 2007 Jun; 12(6):636-43. PubMed ID: 17602055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.
    Tao M; Chen S; Zhang X; Zhou Q
    Medicine (Baltimore); 2017 Dec; 96(51):e9384. PubMed ID: 29390540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Natori A; Ethier JL; Amir E; Cescon DW
    Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
    Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
    Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
    Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
    J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer].
    Qiu AF; Miao ZL; Ge GK; Wang CB; Bian J; Ma HY; Xu Q
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3466-3470. PubMed ID: 29275580
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
    Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
    J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.